JCM
CNST

JS Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

JS Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,800
Closed -$214K – 233
2020
Q1 		$214K Buy
+6,800
New +$236K 0.03% 104

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMV
Venrock Management V Palo Alto, California $719M AUM
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

JS Capital Management's CNST Position: Q2 2020 in Review

JS Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2020, closing a stake of 6,800 shares — an estimated $214K sold.

JS Capital Management first reported a position in CNST in Q1 2020 and held it in 1 quarter. The position peaked at $214K in Q1 2020. 132 funds tracked by Wall St. Rank hold CNST as of Q2 2020.

  • JS Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • JS Capital Management sold 6,800 Constellation Pharmaceuticals, Inc. shares in Q2 2020, an estimated $214K.
  • JS Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • JS Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $214K in Q1 2020.
  • 132 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2020.

Based on JS Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.